BCG predicts rising temperatures will increase default risk in 30% of agri and housing loans by 2030, highlighting climate ...
GlobalData on MSN3d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
Data shows just 2 per cent of total capital raised in Australia in 2024 went to all-female founded teams in 2024. Some of ...
The platform can be harnessed for TB, potentially improving protection and durability of immunity in a way that traditional ...
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
In a tight economy, disciplined cost management is often a better path than absorbing margin pressures or passing costs to ...
ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an "alternative source ...
In a recent Sermo survey of 100 U.S. urologists, 57 percent indicated they were unable to treat patients in the last 12 months due to a lack of access to TICE® BCG. The alternative BCG source has ...
Climate change poses a significant risk to agricultural and housing loans, with default probability increasing due to rising ...
The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback